Olov Wiklund

64.4k citations

158 papers · 13.4k indexed · 5 hit papers · h-index 54

Impact in

Endocrinology, Diabetes and Metabolism top 0.2%
- Diabetes, Cardiovascular Risks, and Lipoproteins
Cardiology and Cardiovascular Medicine top 0.5%

Papers in

Endocrinology, Diabetes and Metabolism 45
- Diabetes, Cardiovascular Risks, and Lipoproteins 38
Biochemistry 14
- Antioxidant Activity and Oxidative Stress 14

Co-authors: Marja‐Riitta Taskinen Alberico L. Catapano Lillemor Mattsson Hultén Jan Borén Göran Bondjers Guy De Backer Gabriele Riccardi Ian Graham
Journals: Atherosclerosis (32 papers)Arteriosclerosis Thrombosis and Vascular Biology (16 papers)Journal of Internal Medicine (13 papers)European Journal of Clinical Investigation (6 papers)Journal of Biological Chemistry (4 papers)
Partner nations: Sweden Italy Finland

In The Last Decade

Olov Wiklund

156 papers receiving 13.0k citations

Hit Papers

5 papers align trajectories log scale

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias 2016 · 2.1k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2016 European Heart Journal
2016 Atherosclerosis
2011 Atherosclerosis
2002 Nature
1995 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by Olov Wiklund

Since Specialization

Citations

This map shows the geographic impact of Olov Wiklund's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olov Wiklund with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olov Wiklund more than expected).

Fields of papers citing papers by Olov Wiklund

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olov Wiklund. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olov Wiklund. The network helps show where Olov Wiklund may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Olov Wiklund, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Olov Wiklund Line = papers co-authored together Olov Wiklund links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Understanding the Patient Perception of Statin Experience: A Qualitative Study Advances in Therapy ·Michal Vráblík, Alberico L. Catapano, Olov Wiklund, Yi Qian, Pratik Rane, Alyson Grove, Mona L. Martin	2019	4
2	Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy Current Cardiology Reports ·Olov Wiklund, Carlo Pirazzi, Stefano Romeo	2013	31
3	The european society of cardiology and the european atherosclerosis society (ESC/EAS) guidelines on the management of dyslipidemia Revista Española de Cardiología ·Željko Reiner, Alberico L. Catapano, Guy De Backer, Iain Graham, Marja‐Riitta Taskinen, Olov Wiklund, Stefan Agewall, Valentina Tessarollo, 马清江, P Durrington, Serap Erdine, Julian Halcox, Richard Hobbs, J Kjekshus, Pasquale Perrone Filardi, David M. Wood, Robert F. Storey, Xiaolan Hou	2011	3
4	Increased lipolysis by secretory phospholipase A₂ group V of lipoproteins in diabetic dyslipidaemia Journal of Internal Medicine ·Christian C. Young, Linda Fogelstrand, Birgitta Rosengren, Muhammed Metin Eskimez, Eva Hurt‐Camejo, Björn Fagerberg, Olov Wiklund	2008	17
5	Efficacy and Tolerability of Rosuvastatin and Atorvastatin when Force-Titrated in Patients with Primary Hypercholesterolemia Cardiology ·Ole Færgeman, Shin Hashimoto, Eberhard Windler, Olov Wiklund, Roland Asmar, Emma Duffield, 高志松原	2008	27
6	Induction of proinflammatory cytokines by long-chain saturated fatty acids in human macrophages Atherosclerosis ·Liliana Håversen, Seo Won Han, Linda Fogelstrand, Olov Wiklund	2008	198
7	Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease SHILAP Revista de lepidopterología ·Sven‐Olof Olofsson, Olov Wiklund, R. Procaccini	2007	32
8	Release of protein as well as activity of MMP‐9 from unstable atherosclerotic plaques during percutaneous coronary intervention Journal of Internal Medicine ·Н. Е. Ившина, Lars Grip, L Hultén, J. Hulthe, Olov Wiklund	2007	21
9	Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5 , shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study Human Molecular Genetics ·Benteng Liu, Cristina Irigoyen-Bañegil, Fotios Drenos, Simon R. Thompson, Jackie A. Cooper, Jeffrey W. Stephens, Steven J. Hurel, Eva Hurt‐Camejo, Olov Wiklund, Steve E. Humphries, Philippa J. Talmud	2007	31
10	Composition of coronary plaques obtained by directional atherectomy in stable angina: its relation to serum lipids and statin treatment Journal of Internal Medicine ·Jan H. Solem, Max Levin, Therese Karlsson, Laura T. Grip, P.Å. Albertsson, Olov Wiklund	2006	13
11	Pathogenesis and treatment of diabetic vascular disease – illustrated by two cases Journal of Internal Medicine ·Ulf Smith, Markku Laakso, Björn Eliasson, Christian Wesslau, Jan Borén, Olov Wiklund, Stig Attvall	2006	5
12	Human macrophages limit oxidation products in low density lipoprotein Lipids in Health and Disease ·Lillemor Mattsson Hultén, Chulhong Oh, Alexandra Krettek, David van Reyk, Stefan L. Marklund, Cláes Dahlgren, Olov Wiklund	2005	14
13	Identification of genes predominantly expressed in human macrophages Atherosclerosis ·Per‐Arne Svensson, Daniel Hägg, Margareta Jernås, Mikael C.O. Englund, Lillemor Mattsson Hultén, Bertil G. Ohlsson, Johannes Hulthe, Olov Wiklund, Björn Carlsson, Björn Fagerberg, Lena Carlsson	2004	21
14	Fatty acids modulate the effect of darglitazone on macrophage CD36 expression European Journal of Clinical Investigation ·L. Svensson, Germán Camejo, Anna Cabré, Joan-Carles Vallvé, Lucie Firlová, Ebad Roohbakhsh, Olov Wiklund, Lillemor Mattsson Hultén	2003	13
15	Hypoxia increases 25-hydroxycholesterol-induced interleukin-8 protein secretion in human macrophages Atherosclerosis ·Ellen Knutsen Rydberg, W. Fischer, Lillemor Mattsson Hultén, Ebad Roohbakhsh, Göran Bondjers, Olov Wiklund, Tom Björnheden, Bertil G. Ohlsson	2003	66
16	Low-density lipoprotein (LDL) binds to a G-protein coupled receptor in human platelets Atherosclerosis ·رحمتالله مرزبند, Eva Hurt‐Camejo, Olov Wiklund, Lina Badimón, L. Masana	2001	14
17	A nine-month, placebo-controlled study of the effects of growth hormone treatment on lipoproteins and LDL size in abdominally obese men Growth Hormone & IGF Research ·Johan Svensson, B.‐Å. Bengtsson, Marja‐Riitta Taskinen, Olov Wiklund, Gudmundur Johannsson	2000	12
18	Lysophosphatidylcholine induces the production of IL-1β by human monocytes Atherosclerosis ·Carlos Alberto Jiménez Arango, Eva Hurt‐Camejo, Olov Wiklund	1998	114
19	Oxysterols present in atherosclerotic tissue decrease the expression of lipoprotein lipase messenger RNA in human monocyte-derived macrophages. Journal of Clinical Investigation ·Lillemor Mattsson Hultén, Helena Lindmark, Ulf Diczfalusy, Ingemar Björkhem, Malin Ottosson, Yang Liu, Göran Bondjers, Olov Wiklund	1996	115
20	Apolipoprotein B in human aortic biopsies in relation to serum lipids and lipoproteins Atherosclerosis ·T. LINDÉN, Göran Bondjers, Gunnar Fager, Sven‐Olof Olofsson, Olov Wiklund	1989	1

About Olov Wiklund

Olov Wiklund is a scholar working on Endocrinology, Diabetes and Metabolism, Biochemistry, Immunology, Surgery and Cancer Research, having authored 158 papers that have together received 13.4k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (60 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (38 papers), Atherosclerosis and Cardiovascular Diseases (35 papers), Cholesterol and Lipid Metabolism (19 papers), Adipokines, Inflammation, and Metabolic Diseases (17 papers), Cancer, Lipids, and Metabolism (17 papers), Lipid metabolism and disorders (14 papers) and Antioxidant Activity and Oxidative Stress (14 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (3.6k citations), Cardiology and Cardiovascular Medicine (3.4k citations), Surgery (6.2k citations), Immunology (2.7k citations) and Cancer Research (1.9k citations). Olov Wiklund has collaborated with scholars based in Sweden, Italy and Finland. Frequent co-authors include Marja‐Riitta Taskinen, Alberico L. Catapano, Lillemor Mattsson Hultén, Jan Borén, Göran Bondjers, Guy De Backer, Gabriele Riccardi, Ian Graham, M. John Chapman and Željko Reiner. Their work appears in journals such as Atherosclerosis, Arteriosclerosis Thrombosis and Vascular Biology, Journal of Internal Medicine, European Journal of Clinical Investigation and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact